Results 181 to 190 of about 81,406 (283)

M2 macrophages predict response to neoadjuvant chemotherapy in triple negative breast cancer patients. [PDF]

Sci Rep
Chen WX, Yang M, Shao QF, Zhu B, Xue J, Zheng L, Qin XH, Qi CJ.   +7 more
europepmc   +1 more source

Garcinone C Suppresses Cancer Stem Cells and Induces Apoptosis in Triple‐Negative Breast Cancer Through Canonical Wnt Signaling

Food Frontiers, Volume 7, Issue 3, May 2026.
Garcinone C (Gar. C), a xanthone derived from mangosteen (Garcinia mangostana), suppresses triple‐negative breast cancer growth and stemness by inducing mitochondrial‐mediated apoptosis and inhibiting the Wnt/β‐catenin pathway, highlighting its potential as a natural compound for the prevention and treatment TNBC.
Danhong Zheng, Jiazi Chen, Yong Wang, Da Ma, Jing Chen   +4 more
wiley   +1 more source

Metformin drives HIF-1α-mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer. [PDF]

Cancer Immunol Immunother
Qin X, Zhong H, Liu M, Yu T, Ma R, Zhou Y, Chen J, Liu F, Wang X, Long J.   +9 more
europepmc   +1 more source

Synthesis, Characterization, and Cytotoxic Activity Properties of Some Novel Purine Derivatives

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 5, May 2026.
Nine novel purine derivatives were successfully synthesized and its cytotoxic activities were evaluated against HepG2 and MDA‐MB‐231 cancer cell lines. ABSTRACT This study reports the synthesis of nine new compounds with purine scaffolds. It thoroughly analyzes them using a variety of spectroscopic methods, including high‐resolution mass spectrometry ...
Nurdan Akdoğan, Ayşenur Işgüzar, Senem Akkoc, Muhammed Tilahun Muhammed, Sadeq K. Alhag, Laila A. Al‐Shuraym, Ali Dişli   +6 more
wiley   +1 more source

Discrimination of Triple-Negative Breast Cancer: A Robust Clinical Baseline versus Multimodal Magnetic Resonance Imaging Integrated Models with Assessment of Generalizability. [PDF]

Breast Cancer (Dove Med Press)
Liao X, Wu X, Zheng J, Lin G, Lin D.
europepmc   +1 more source

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Systematic Review of Breast and Node Pathologic Response

Journal of Surgical Oncology, Volume 133, Issue 6, Page 712-719, May 2026.
ABSTRACT Introduction Pathological complete response (pCR) after neoadjuvant chemotherapy is associated with improved prognosis in patients with triple‐negative breast cancer (TNBC). Differences in pathological response rates between the breast and axillary lymph nodes have prompted interest in understanding response patterns that may, in the future ...
Milena Martello Cristófalo, Jonathan Yugo Maesaka, Deise Azevedo Pereira, Gabriela Bezerra Nóbrega, Yedda Nunes Reis, José Maria Soares Júnior, Edmund Chada Baracat, José Roberto Filassi   +7 more
wiley   +1 more source

Integrated single-cell and spatial mapping coupled with machine learning unveils core stemness landscapes and regulatory drivers in triple-negative breast cancer. [PDF]

Discov Oncol
Huo Z, Sun W, Lou C, Yang T.
europepmc   +1 more source

RNA Modifications: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 5, May 2026.
Types of RNA modification. We have summarized the currently common types of RNA modifications, including ac4C, m6A, m1A, m5C, m3C, m7G, and ψ, and visually characterized their features through structural formulas. The characteristic structures are marked with a background color different from the background color.
Shiyu Xiao, Tingwen Xiang, Chuan Yang, Xiaohua Wang, Gang Huang, Fei Luo, Zhao Xie, Yueqi Chen   +7 more
wiley   +1 more source

Decoding the Clinical and Therapeutic Significance of MEAK7 in Triple-Negative Breast Cancer Through Integrative Bioinformatics. [PDF]

Biology (Basel)
Ayan D, Kan MU, Bayram E, Soylemez S.
europepmc   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, Volume 183, Issue 9, Page 1727-1746, May 2026.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source